INTRODUCTION
Previous quantitative studies of the urinary metabolites of cinnamic acid in human subjects have given promise of yielding data of clinical value in hepatic disease (1, 2) . As is well known from both animal and human experiments, this relatively non-toxic substance is converted to and excreted as hippuric acid in the urine. The possibilities of this test material as-a model for the study of the rate of beta-oxidation by the liver of the intact subject were first suggested by Snapper (3) . Snapper, Yu and Chiang demonstrated that, in the human subject, the portion of cinnamate which escaped oxidation was excreted by conjugation as cinnamoylglucuronic acid (4) . Furthermore, in their subjects free cinnamic acid and cinnamoylglycine were not detected.
After oral administration of 6.9 grams of sodium cinnamate, Snapper and Saltzman showed (2) that normal subjects oxidize the main part of the cinnamate to benzoate, the remainder being conjugated as a glucuronide. In liver disease the rate of oxidation of cinnamate was decreased, and when the benzoate was produced more rapidly than it could be removed by an impaired glycine conjugation mechanism, benzoylglucuronide was formed. It was also found that by giving comparable amounts of the more insoluble and slowly absorbed cinnamic acid rather than its salt, there was a more complete oxidation of cinnamate to benzoate and less glucuronide excretion in the urine.
It would appear from the above that the preferred metabolic pathway is beta-oxidation to benzoate, with a secondary mechanism of removal as cinnamoylglucuronic acid. That the latter "defense" mechanism can be brought into greater use with impairment of oxidative function was seen in hepatic disturbances where a uniform dose of 3 grams of cinnamic acid was given to all subjects. Upon administration of the latter, a semiquantitative test for excessive excretion of glucuronides was performed on fractional urine specimens. In normal subjects there was little or no reaction with the naphthoresorcinol reagent while in hepatocellular disease almost all subjects tested showed increased excretion of glucuronides, often with a lag period. By comparison with the benzoylglucuronic acid test, greater sensitivity was noted with cinnamic acid as the test substance.
The lack of sensitivity of the oral benzoic acidtest has also been noted by Sharnoff To indicate the precision of the method, in a series of 100 consecutive analyses, the duplicate determinations differed by a mean of 0.10 mg. per 100 ml. serum (S.D. = 0.08). In addition it was thought worthwhile to determine the lowest level of cinnamic acid concentration which could be determined with accuracy by the ultraviolet technique in order to establish the significance of cinnamic acid levels reported in the lower range (0.3 to 2.0 mg. per 100 ml.). Recovery experiments with concentrations at intervals in this range indicated an. accuracy within 0.1 mg. per 100 ml., sufficient for our purposes.
Following intravenous administration the cinnamate disappears rapidly from the blood. By measuring the concentration of serum cinnamate at intervals in five subjects, it was found that the decrease in concentration with time was logarithmic, i.e., followed a first order reaction as shown in Figure 2 . The rate of decline of cinnamate level is equal to the value for the slope of the straight line and is expressed as per cent change in concentration per minute:
The hippuric acid in urine was determined by the gravimetric procedure of Quick with the addition of ammonium sulfate to decrease the solubility of the hippuric acid in the-filtrate (9) . Results are expressed as per cent conversion of cinnamic to hippuric acids in the six hour interval.
OBSERVATIONS
The data obtained with the oral cinnamic acid test are shown in Figure 3 . The peak serum cinnamic acid level was reached in either the 1st or 2nd hour specimen in 19 out 'of 20 subject's studied hourly for four hours after cinnamic acid ingestion. Because of the variation shown in the rate of intestinal absorption, the mean 1 and 2 hour level was taken for comparative purposes. In 23 normal subjects the serum cinnamic acid level was in In Figure 5 Figure 6 ). This is a statistically significant difference. In this regard it is of interest that in ten unselected hepatitis or cirrhosis patients in whom repeat determinations were made, elevated values returned to normal in the patients undergoing remission and were unchanged in the unimproved (Table I) . With the glucuronic acid method of Fishman, Smith, Thompson, Bonner, Kasdon, and Homburger, a correction for glucose content was not found significant in the normal or liver damage group, but of importance in the diabetic where the deviation due to glucose may be large (10) . DISCUSSION A summary of recorded observations of metabolic pathways in the fate of cinnamic acid after ingestion by human subjects is indicated in Figure 7 . These data are based on measurements of conjugation products excreted in the urine. In the dosage given the normal pathway (counterclockwise in Figure 7 ) is largely by beta oxidation to benzoic acid and conjugation of the latter with glycine to form hippuric acid. In liver damage there is diminished oxidation to benzoate and diminished glycine production and conjugation, with greater use of the glucuronic acid conjugation-system (clockwise in Figure 7 concomitant decreased excretion of hippuric acid in the urine. Since the glucuronic acid level was unchanged over the control value, it can be assumed that the excess of unoxidized cinnamate was circulating as a sodium salt rather than as a conjugated compound. No significant change was noted in the glucose and phosphorus levels in the patients studied. The latter indicated that the intact human being given the dosage employed in this study reacts differently from isolated rat and guinea pig kidney and liver slices as studied by Weinbach, Lowe, Frisell, and Hellerman (11) . They noted that the presence of cinnamate will presumably increase the rate of utilization of glucose as seen from lactate accumulation which is paralleled by increased glucose removal.
The In two patients with multiple myeloma, the rate of removal of cinnamate was increased to almost twice normal. It follows that this may be due, in part, to the metabolic activity of the myeloma cells. In one patient in whom the latter was suppressed by urethane and cortisone, K values dropped to normal.
A mild elevation in the fasting glucuronic acid levels in a proportion of patients with liver disease was noted, along with a rapid return to normal early in the course of -improvement. If further observations bear out this finding, it may be a prognostic guide with these pa;tients. Simultaneous glucose determinations were in the normal range. While large doses of drugs may cause glucuronic acid elevation, most of the liver patients received only diet and vitamifts and had the above mentioned changes with continuation of the same therapy. These data may be interpreted as indicating the greater use of glucuronide conjugation mechanism in the acute phase of liver injury, possibly for the removal of endogenous metabolites that are not handled through their normal pathways. In that respect, it may parallel the increased glucuronide conjugation with benzoic or cinnamic acids as test materials when the primary methods of removal, glycine conjugation and oxidation, respectively, are impaired. 
